AR103719A1 - Composición líquida tópica para el lavado intrauterino que contiene melatonina - Google Patents
Composición líquida tópica para el lavado intrauterino que contiene melatoninaInfo
- Publication number
- AR103719A1 AR103719A1 ARP160100421A ARP160100421A AR103719A1 AR 103719 A1 AR103719 A1 AR 103719A1 AR P160100421 A ARP160100421 A AR P160100421A AR P160100421 A ARP160100421 A AR P160100421A AR 103719 A1 AR103719 A1 AR 103719A1
- Authority
- AR
- Argentina
- Prior art keywords
- melatonin
- liquid composition
- composition
- topical liquid
- arginine
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 8
- YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 title abstract 5
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 title abstract 5
- 229960003987 melatonin Drugs 0.000 title abstract 4
- 239000007788 liquid Substances 0.000 title abstract 3
- 230000000699 topical effect Effects 0.000 title abstract 3
- 238000005406 washing Methods 0.000 title 1
- 239000004475 Arginine Substances 0.000 abstract 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 abstract 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 abstract 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 abstract 1
- 229920001213 Polysorbate 20 Polymers 0.000 abstract 1
- 230000004720 fertilization Effects 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 238000002513 implantation Methods 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 229930182817 methionine Natural products 0.000 abstract 1
- 239000008363 phosphate buffer Substances 0.000 abstract 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 abstract 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 abstract 1
- 229940068977 polysorbate 20 Drugs 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000011780 sodium chloride Substances 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Inorganic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Pregnancy & Childbirth (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Formulación a base de melatonina, en particular una composición líquida tópica de melatonina (o un análogo de la misma) adecuada para uso en el lavado intrauterino realizado durante la reproducción asistida médicamente (por ejemplo, la fertilización in vitro - IVF). Las composiciones exhiben una alta estabilidad, lo que les permite mantenerse durante períodos prolongados antes de su uso eventual para la inhibición o la prevención del fallo en la implantación embrionaria. Reivindicación 16: La composición líquida tópica de acuerdo con la reivindicación 1, en la que la composición contiene: 15 a 25 ng/ml de melatonina (N-acetil-5-metoxitriptamina) o un análogo de la misma, o una sal o solvato farmacéuticamente aceptable de la misma; y sistema de búfer de fosfato de 5 a 15 mM; 0,005 a 0,015 mg/ml de metionina; 0,04 a 0,4 mg/ml de arginina (proporcionada convenientemente como desde aproximadamente 0,05 - 0,5 mg/ml de la arginina.HCl); 5 a 12 mg/ml de cloruro de sodio; desde 0,025 hasta 0,075 mg/ml de polisorbato 20; agua (como el saldo restante en peso); donde el pH de la composición es un pH de 7,6 a 7,8, y la composición tiene una Osmolaridad de 295 a 320 mOsm/kg.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15155389 | 2015-02-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR103719A1 true AR103719A1 (es) | 2017-05-31 |
Family
ID=52595073
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP160100421A AR103719A1 (es) | 2015-02-17 | 2016-02-17 | Composición líquida tópica para el lavado intrauterino que contiene melatonina |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US10188631B2 (es) |
| EP (1) | EP3258910A1 (es) |
| JP (1) | JP6889117B2 (es) |
| KR (1) | KR20170116152A (es) |
| CN (1) | CN107249572A (es) |
| AR (1) | AR103719A1 (es) |
| AU (2) | AU2016221796A1 (es) |
| BR (1) | BR112017017432A2 (es) |
| CA (1) | CA2975331A1 (es) |
| HK (1) | HK1243649A1 (es) |
| IL (1) | IL253934A0 (es) |
| MX (1) | MX2017010555A (es) |
| RU (1) | RU2017132292A (es) |
| SG (1) | SG11201706363QA (es) |
| WO (1) | WO2016131784A1 (es) |
| ZA (1) | ZA201705632B (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019038586A1 (en) | 2017-08-19 | 2019-02-28 | Ftf Pharma Private Limited | PHARMACEUTICAL COMPOSITION OF MELATONIN |
| WO2019147026A1 (ko) * | 2018-01-23 | 2019-08-01 | 차의과학대학교 산학협력단 | 멜라토닌을 포함하는, 배아 발달용 조성물 및 이를 이용하여 배아 발달의 효율을 향상시키는 방법 |
| CN116267895A (zh) * | 2022-08-03 | 2023-06-23 | 北京市农林科学院 | 褪黑素核受体RORα在提高冷冻精液品质中的用途 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1312377B1 (it) * | 1999-03-05 | 2002-04-15 | Uni Ci S R L | Composizioni a base di acido tiottico, cisteina e/o n-acetil cisteinada utilizzarsi in preparazioni farmaceutiche, dietetiche e cosmetiche |
| US8415094B2 (en) * | 2007-12-21 | 2013-04-09 | Jaffar Ali bin M. Abdullah | Protein-free gamete and embryo handling and culture media products |
| ITMI20120913A1 (it) * | 2012-05-28 | 2013-11-29 | Nicoletta Maxia | Uso della n-acetil-5-metossitriptamina o suoi analoghi per favorire il meccanismo di impianto dell' embrione, e relative composizioni e mezzi di coltura |
-
2016
- 2016-02-15 US US15/548,315 patent/US10188631B2/en not_active Expired - Fee Related
- 2016-02-15 RU RU2017132292A patent/RU2017132292A/ru unknown
- 2016-02-15 MX MX2017010555A patent/MX2017010555A/es unknown
- 2016-02-15 BR BR112017017432-4A patent/BR112017017432A2/pt not_active IP Right Cessation
- 2016-02-15 SG SG11201706363QA patent/SG11201706363QA/en unknown
- 2016-02-15 EP EP16704628.3A patent/EP3258910A1/en not_active Withdrawn
- 2016-02-15 AU AU2016221796A patent/AU2016221796A1/en not_active Abandoned
- 2016-02-15 KR KR1020177025750A patent/KR20170116152A/ko not_active Application Discontinuation
- 2016-02-15 WO PCT/EP2016/053197 patent/WO2016131784A1/en active Application Filing
- 2016-02-15 CN CN201680010542.4A patent/CN107249572A/zh active Pending
- 2016-02-15 CA CA2975331A patent/CA2975331A1/en not_active Abandoned
- 2016-02-15 JP JP2017561037A patent/JP6889117B2/ja active Active
- 2016-02-17 AR ARP160100421A patent/AR103719A1/es unknown
-
2017
- 2017-08-09 IL IL253934A patent/IL253934A0/en unknown
- 2017-08-18 ZA ZA2017/05632A patent/ZA201705632B/en unknown
-
2018
- 2018-03-08 HK HK18103278.7A patent/HK1243649A1/zh unknown
-
2021
- 2021-03-24 AU AU2021201851A patent/AU2021201851A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US10188631B2 (en) | 2019-01-29 |
| AU2016221796A1 (en) | 2017-08-17 |
| JP2018510210A (ja) | 2018-04-12 |
| WO2016131784A1 (en) | 2016-08-25 |
| SG11201706363QA (en) | 2017-09-28 |
| HK1243649A1 (zh) | 2018-07-20 |
| BR112017017432A2 (pt) | 2018-04-03 |
| RU2017132292A (ru) | 2019-03-18 |
| JP6889117B2 (ja) | 2021-06-18 |
| US20180021308A1 (en) | 2018-01-25 |
| ZA201705632B (en) | 2018-12-19 |
| MX2017010555A (es) | 2017-12-07 |
| AU2021201851A1 (en) | 2021-04-22 |
| RU2017132292A3 (es) | 2019-08-21 |
| CN107249572A (zh) | 2017-10-13 |
| KR20170116152A (ko) | 2017-10-18 |
| CA2975331A1 (en) | 2016-08-25 |
| IL253934A0 (en) | 2017-10-31 |
| NZ734192A (en) | 2020-11-27 |
| EP3258910A1 (en) | 2017-12-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY38001A (es) | Compuestos que inhiben las proteínas ras mutantes g12c | |
| AR083879A1 (es) | Analogos de aminoglicosidos antibacterianos, metodos de preparacion y uso como agentes terapeuticos | |
| AR090456A1 (es) | Combinaciones farmaceuticas que comprenden un analogo de tionucleotidos | |
| BR112015025766A2 (pt) | derivado de nucleosídeo altamente ativo para o tratamento de hcv | |
| CO6531469A2 (es) | Derivados de purina o deazapurina utiles para el tratamiento de (entre otros) infecciones virales | |
| AR072261A1 (es) | Derivados piperazin-pirazolicos, composiciones farmaceuticas que los contienen y usos de los mismos como agentes anticancerigenos. | |
| CO6680698A2 (es) | Formulación de premezcla de dexmedetomidina | |
| BR112015023412A8 (pt) | 3-pirimidin-4-il-oxazolidin-2-onas como inibidores de idh mutante, sua composição farmacêutica e seu uso. | |
| AR082024A1 (es) | Formulacion de anticuerpo contra ox40l humano | |
| AR069490A1 (es) | Agonistas de los receptores de glucocorticoides | |
| UY33501A (es) | Derivados de acil sulfonamida y sus sales farmacéuticamente aceptables para uso en medicina | |
| NI201200172A (es) | Activadores de guanilato ciclasa soluble | |
| CL2019002190A1 (es) | Reducción de la viscosidad de formulaciones farmacéuticas que comprende una proteína terapéutica a una concentración de al menos 70 mg/ml, donde la proteína terapéutica no es un anticuerpo (divisional solicitud 201700984) | |
| PE20130217A1 (es) | Composiciones farmaceuticas y metodos para su elaboracion | |
| BR112012000287B8 (pt) | composição farmacêutica para um inibidor de protease viral de hepatite c | |
| CR20190433A (es) | Compuestos de pirimidinil-pyridiloxi-naftil y métodos para tratar enfermedades y trastornos relacionados con ire1 | |
| HN2008001666A (es) | Derivados acidos de cicloalquilamino | |
| RU2016135952A (ru) | Композиции ингибитора дофа-декарбоксилазы | |
| PH12016502100A1 (en) | Liquid formulation comprising gm-csf neutralizing compound | |
| AR078722A1 (es) | Derivados de 2-oxo-1-pirrolidinila imidazotiadiazol | |
| AR103719A1 (es) | Composición líquida tópica para el lavado intrauterino que contiene melatonina | |
| AR051797A1 (es) | Derivados de hidantoina inhibidores de metaloproteinasas | |
| JP2017514924A5 (es) | ||
| AR109168A1 (es) | Sales de derivados de 2,6-dimetilpirimidona y sus usos | |
| BR112015005347A2 (pt) | composto, composição farmacêutica, e, método para tratamento ou profilaxia de infecção por hiv ou para tratamento, profilaxia, ou atraso no início de aids |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |